Detection method for HER2 related exosome and application thereof
Through the specific identification and enrichment technology of biDNA tetrahedral nanomaterials, the complexity and cost of existing HER2-related exosome detection methods are solved, and accurate detection and prognostic evaluation of HER2-positive breast cancer is achieved.
Patent Information
- Application Number
- CN202411059105.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-12-03
AI Technical Summary
The existing HER2-related exosome detection methods are complex in operation, long time and high in cost, and are difficult to widely use in clinical practice.
Using bi-DNA tetrahedral nanomaterials, the enrichment and detection of HER2-related exosomes is achieved by specifically identifying HER2 and CD63 on the exosome surface. The combined structure of precipitated crosslinked tetrahedron and HER2 is used to identify the combined structure of tetrahedrons and HER2, combined with HCR Reaction to achieve accurate detection of HER2-related exosomes.
It improves the enrichment effect of HER2-related exosomes, provides an economical and easy-to-operate detection method, which can more accurately detect the occurrence, development and prognosis of HER2-positive breast cancer, and is conducive to screening, diagnosis and metastasis evaluation.
Smart Images

Figure CN119064576A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and specifically to a detection method for HER2-related exosomes and an application thereof. Background Art
[0002] HER2, or human epidermal growth factor receptor 2, is a protein present on the cell membrane and belongs to the tyrosine kinase receptor family. HER2 protein regulates cell growth and division under normal circumstances, but when the HER2 gene is amplified or overexpressed, it will lead to abnormal cell proliferation, which may cause cancer, especially breast cancer.
[0003] HER2 has important biological and clinical significance in HER2-positive breast cancer. HER2-positive breast cancer is usually more invasive and has a worse prognosis due to HER2 gene amplification and protein overexpression. However, with HER2-targeted therapies, such as trastuzumab, pertuzumab, and T-DM1, the treatment effect and survival rate of patients have been significantly improved. Therefore, the detection of HER2 status and targeted therapy are the key to the management of HER2-positive breast cancer.
[0004] Tumor-associated exosomes are nanoscale vesicles secreted by tumor cells, with a diameter of approximately 30-150 nanometers. Exosomes play an important role in intercellular communication, affecting tumor microenvironment, immune escape, metastasis and drug resistance by delivering biological molecules such as proteins, lipids, RNA and DNA. Protein expression on the surface of exosomes can reflect the biological characteristics of tumor cells. Therefore, enrichment detection of exosomes that specifically express proteins in the blood can guide the occurrence and development of tumors from a quantitative perspective.
[0005] At present, the main methods for extracting and detecting exosomes include ultracentrifugation, size exclusion chromatography, immunocapture, microfluidics, nanoparticle tracking analysis, and flow cytometry. However, these methods are difficult to be widely used and popularized in clinical practice due to their complex operation, long time consumption, and high cost. To address this problem, we studied a double DNA tetrahedron nanomaterial that specifically recognizes HER2 and CD63 on the surface of exosomes, thereby enriching and detecting HER2-expressing exosomes. Because this method is economical and easy to operate, it is of great help in the diagnosis and prognosis of clinical HER2-positive breast cancer. Summary of the invention
[0006] The object of the present invention is to provide a method for detecting HER2-related exosomes, so as to accurately quantify HER2-related exosomes in a sample.
[0007] To achieve the above object, the present invention provides the following technical solutions:
[0008] In a first aspect, the present invention provides a probe enrichment complex for detecting HER2-related exosomes, wherein the complex comprises the following two DNA tetrahedral nanomaterials: a precipitated cross-linked tetrahedron and a HER2 recognition tetrahedron, wherein the four vertices of the precipitated cross-linked tetrahedron have overhang chains, one vertex overhang chain contains a CD63 aptamer, and the other three vertex overhang chains can be cross-linked with each other; the four vertices of the HER2 recognition tetrahedron also have overhang chains, one vertex overhang chain contains a HER2 aptamer, and the other three vertex overhang chains can trigger an HCR reaction.
[0009] Preferably, in the complex, the precipitated cross-linked tetrahedron is assembled from nucleotide sequences of SeqNo.1 to 5, the HER2 recognition tetrahedron is assembled from nucleotide sequences of SeqNo.6 to 10, and further comprises DX connector sequences SeqNo.13 to 14, wherein the DX connector sequences can be complementary to the vertex overhang chains of the precipitated cross-linked tetrahedron for cross-linking for cross-linking of the precipitated cross-linked tetrahedron.
[0010] Preferably, during assembly, the sequences of SeqNo.1 to 5 are in an equal molar ratio, and the sequences of SeqNo.6 to 10 are in an equal molar ratio.
[0011] In a second aspect, the present invention further provides a kit for detecting HER2-related exosomes, the kit comprising the following components: the complex as described above and an HCR initiating sequence that is complementary to the vertex overhanging chain of the HER2 recognition tetrahedron capable of initiating an HCR reaction, thereby initiating an HCR reaction.
[0012] Preferably, a detectable group is attached to the HCR triggering sequence.
[0013] Preferably, the HCR initiating sequence is the sequence shown in SeqNo.11-12.
[0014] Preferably, the kit further comprises a tetrahedral assembly buffer solution, the composition of which at a working concentration is: 40 mM tris(hydroxymethyl)aminomethane, 40 mM glacial acetic acid, 1 mM ethylenediaminetetraacetic acid and 12.5 mM Mg2+, pH=8.0.
[0015] Preferably, the kit further comprises a control standard, i.e., a HER2-related exosome sample with a known concentration.
[0016] In a third aspect, the present invention also provides a method for detecting the concentration of HER2-related exosomes in a sample, comprising the following steps:
[0017] 1) preparing precipitated cross-linked tetrahedrons and HER2 recognition tetrahedrons, adding them to samples to allow the tetrahedrons to bind to HER2-related exosomes in the samples, wherein the HER2 recognition tetrahedrons contain HCR reaction initiating fragments;
[0018] 2) Adding double cross-linking structure promotes tetrahedral cross-linking;
[0019] 3) Enrichment of HER2-associated exosomes;
[0020] 4) adding an HCR reaction initiator sequence to the enriched HER2-related exosomes, wherein the HCR reaction initiator sequence is connected to a detectable group;
[0021] 5) Detecting the signal of the detectable group.
[0022] Preferably, the method further comprises the steps of drawing a standard curve according to the detection results of the standard substance, and comparing the results obtained by detecting the signal of the detectable group with the standard curve.
[0023] Compared with the prior art, the beneficial effects of the present invention are as follows: the present invention uses double DNA tetrahedron nanomaterials to detect the concentration of HER2-related exosomes in samples, which has a better enrichment effect on HER2-related exosomes than traditional methods, thereby providing an effective means for accurate concentration detection. By means of the above enrichment means to detect samples, it was found that the increase in the level of HER2-related exosomes in human serum is closely related to the occurrence and development of HER2-positive breast cancer. With more accurate detection, the use of double DNA tetrahedron nanomaterials can play a role in screening, diagnosis, transfer, and prognosis evaluation of HER2-positive breast cancer, and can also play a role in distinguishing breast cancer patients with different HER2 expression levels. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 It is a schematic diagram of the technical solution of the method of the present invention;
[0025] Figure 2 This is the electrophoresis diagram of DNA tetrahedron assembly;
[0026] Figure 3 For the characterization of enriched HER2-associated exosomes;
[0027] Figure 4 To determine the differences in serum HER2-related exosome levels among different clinical populations. DETAILED DESCRIPTION
[0028] The present invention provides a method for detecting HER2-related exosomes, which utilizes double DNA tetrahedron nanomaterials to enrich and detect HER2-related exosomes in serum, thereby predicting and evaluating the diagnosis and metastasis of HER2-positive breast cancer patients.
[0029] The specific technical principle is that we designed a double DNA tetrahedron nanomaterial. The double DNA tetrahedron nanomaterial includes two tetrahedral structures. One of the structures is equipped with capture chains at three vertices to cross-link multiple target extracellular vesicles, while the remaining vertex is modified with an aptamer that can recognize the typical EVs membrane protein CD63. The other structure has initiator chains at three vertices to trigger the hybridization chain reaction (HCR), while the remaining vertex is modified with an aptamer targeting the HER2 protein. Only when CD63 and HER2 coexist in the same exosome can the fluorescent signal be generated and detected. For the specific principle, see Figure 1 .
[0030] The method for detecting HER2-related exosomes of the present invention can be used in the following applications:
[0031] 1) Preparation of products for HER2-positive breast cancer screening;
[0032] 2) Preparation of products for diagnosis of HER2-positive breast cancer;
[0033] 3) Preparation of products for assessing the risk of metastasis of HER2-positive breast cancer;
[0034] 4) Preparation of products for prognosis assessment of HER2-positive breast cancer;
[0035] 5) Prepare products to identify and distinguish different HER2 expression levels in breast cancer.
[0036] In an exemplary embodiment, the product is a reagent or a detection kit for detecting DNA tetrahedral nanomaterials of HER2-associated exosomes.
[0037] In a further exemplary embodiment, the detection reagent is a DNA tetrahedron nanomaterial, and the kit includes a DNA tetrahedron having a cross-linking precipitation function and a DNA tetrahedron nanomaterial having a HCR reaction triggering function.
[0038] In an exemplary embodiment, the reagents used in the double DNA tetrahedron nanoprecipitation detection method include:
[0039] 1) Weight-TDN (precipitation of tetrahedral structures of multiple exosomes): It is prepared by annealing four single-stranded DNA chains (Tetra-1-A, Tetra-1-B, Tetra-1-C and Tetra-1-D) and CD63 nucleic acid aptamers at a ratio of 1:1:1:1:1, with a final concentration of 2 μM;
[0040] 2) HCR-TDN (tetrahedral structure that triggers HCR reaction): It is obtained by annealing four single-stranded DNAs (Tetra-2-A, Tetra-2-B, Tetra-2-C, Tetra-2-D) and the HER2 aptamer at the same ratio of 1:1:1:1:1, with a final concentration of 2 μM;
[0041] 3) Double cross-link structure (DX connector): M1 and M2 were mixed in the same ratio (the final concentration of each chain was 6 μM) in 1*TAE Mg2+ buffer solution and assembled by annealing in a PCR instrument;
[0042] 4) HCR priming sequence: FAM-H1-BHQ and H2, at concentrations of 3 μM and 15 μM;
[0043] 5) Tetrahedral assembly buffer solution (1*TAE Mg2+, pH=8.0): 40 mM tris(hydroxymethyl)aminomethane, 40 mM glacial acetic acid, 1 mM ethylenediaminetetraacetic acid and 12.5 mM Mg2+;
[0044] 6) carbonate buffer solution (PBS, pH = 7.4): 10 mM sodium dihydrogen phosphate, 10 mM sodium bicarbonate, 137 mM sodium chloride and 2.5 mM Mg;
[0045] 7) Standard: HER2-related exosome samples with known concentrations.
[0046] In a further exemplary embodiment, the specific steps of using the above double DNA tetrahedron nanomaterial to detect the concentration of HER2-related exosomes are:
[0047] 1) Add 20 μL of 2 μM Weight-TDN and 20 μL of 2 μM HCR-TDN to 160 μL of serum solution and incubate at room temperature for 2 hours;
[0048] 2) Subsequently, free TDN was removed by centrifugation, and 20 μL of 6 μM DX linker was added to the solution obtained after centrifugation, and incubated at room temperature for 30 minutes;
[0049] 3) Centrifuge at 20,000 x g for 30 min, remove the supernatant, and resuspend the precipitated exosomes in 80 μL of PBS;
[0050] 4) Add 10 μL of 3 μM F-H1-Q and 10 μL of 15 μM H2 to 80 μL of enriched exosomes and incubate at room temperature for 2 hours. The initiating chain on HCR-TDN will trigger the H1 chain, thereby initiating the HCR reaction, thereby achieving the purpose of amplifying the fluorescence signal;
[0051] 5) The emission spectrum of Fam dye was measured by fluorescence microplate reader with an excitation wavelength of 488 nm to measure the absorbance intensity at a wavelength of 522 nm;
[0052] 6) A standard curve was drawn using the concentration of the standard and the corresponding fluorescence signal. The common logarithm of the HER2-related exosome level value was taken from the control standard curve. The 1U / μL HEVs level refers to the presence of 10^1 tumor-derived extracellular vesicle particles per μL.
[0053] The present invention also provides a kit, which includes the reagent or the step for detecting HER2-related exosomes.
[0054] The following will be combined with the specific embodiments of the present invention and the accompanying drawings to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0055] In the description of the present invention, it should be noted that the terms "upper", "lower", "inner", "outer", "front end", "rear end", "two ends", "one end", "the other end" and the like indicating the orientation or positional relationship are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operate in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first" and "second" are only used for descriptive purposes and cannot be understood as indicating or implying relative importance.
[0056] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "provided with", "connected", etc. should be understood in a broad sense. For example, "connected" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0057] Example 1
[0058] Assembly of DNA Tetrahedron
[0059] DNA tetrahedrons are assembled in the following steps:
[0060] 1) Weight-TDN (tetrahedral structure of precipitated cross-linked multiple exosomes) was obtained by annealing four single-stranded DNA chains (Tetra-1-A, Tetra-1-B, Tetra-1-C and Tetra-1-D) and CD63 nucleic acid aptamer at a ratio of 1:1:1:1:1. M1 and M2 were added to the assembled tetrahedron in the same ratio (final concentration of each chain was 2 μM) and mixed in 1*TAEMg2+ buffer solution, and annealed by PCR instrument to assemble into a symmetrical double cross-linked structure.
[0061] 2) HCR-TDN (tetrahedral structure that triggers HCR reaction) is obtained by annealing four single-stranded DNAs (Tetra-2-A, Tetra-2-B, Tetra-2-C, Tetra-2-D) and HER2 aptamers in the same ratio.
[0062] 3) The five chains of the two TDNs were kept at 95°C for two minutes in 1*TAEMg2+ buffer solution with a final concentration of 2 μM, and then quickly annealed to 10°C and kept for 20 minutes.
[0063] 4) The two assembled DNA tetrahedrons were analyzed by 6% non-denaturing polyacrylamide gel electrophoresis. The buffer solution used for electrophoresis was 1*TAE, Mg2+ buffer solution. The electrophoresis was performed at a constant power of 6W and on ice for about 2-4 hours. After the electrophoresis was completed, the gel in the running area was cut out and stained with GelRed dye for 5-10 minutes, and then analyzed by a gel imaging system.
[0064] Figure 2 The results of gel electrophoresis are shown, where Figure 2Lane 1 in A is Tetra-1-A; Lane 2 is formed by annealing Tetra-1-A and Tetra-1-B at a ratio of 1:1; Lane 3 is formed by annealing Tetra-1-A, Tetra-1-B and Tetra-1-C at a ratio of 1:1:1; Lane 4 is formed by annealing Tetra-1-A, Tetra-1-B, Tetra-1-C and Tetra-1-D at a ratio of 1:1:1:1; Lane 5 is formed by annealing Tetra-1-A, Tetra-1-B, Tetra-1-C, Tetra-1-D and CD63 nucleic acid aptamer at a ratio of 1:1:1:1:1; Lane 6 is DX connector; Lane 7 is formed by annealing Tetra-1-A, Tetra-1-B, Tetra-1-C, Tetra-1-D, CD63 nucleic acid aptamer and DX connector at a ratio of 1:1:1:1:1:1. As the number of DNA tetrahedron chains increases, the mobility of the main bands in lanes 1-5 decreases, indicating that the ssDNA chains are successfully assembled into tetrahedral structures. Lanes 6 and 7 show that the DX connector is successfully assembled and hybridized to the tetrahedron ( Figure 2 A). Similarly, we verified the assembly of the HCR-TDN nanostructure. Figure 2 Lane 1 in B is Tetra-2-A; Lane 2 is Tetra-2-A and Tetra-2-B annealed at a ratio of 1:1; Lane 3 is Tetra-2-A, Tetra-2-B and Tetra-2-C annealed at a ratio of 1:1:1; Lane 4 is Tetra-2-A, Tetra-2-B, Tetra-2-C and Tetra-2-D annealed at a ratio of 1:1:1:1; Lane 5 is Tetra-2-A, Tetra-2-B, Tetra-2-C, Tetra-2-D and HER2 nucleic acid aptamer annealed at a ratio of 1:1:1:1:1. The assembled structure shows a clear main band on the gel, and the migration rate of the final product is slower than the expected migration rate of each component chain ( Figure 2 B). Finally, we verified the possibility of HCR-TDN triggering HCR by native polyacrylamide gel electrophoresis. Figure 2 Lane 1 in C is FAM-H1-BHQ; Lane 2 is H2; Lane 3 is a mixture of FAM-H1-BHQ and H2; Lane 4 is HCR-TDN; Lane 5 is a mixture of HCR-TDN, FAM-H1-BHQ and H2. The results show that, as shown in lanes 1-3, no new bands were observed when only F-H1-1 and H2 were mixed, indicating that the two chains coexisted stably. After adding HCR-TDN, multiple bands appeared (lane 5), indicating that HCR was successfully triggered ( Figure 2 C) Further verify the stability of TDN. Figure 2Lanes 1-4 in D are respectively Weight-TDN in PBS buffer at room temperature for 0 h, 2 h, 6 h, and 10 h; Figure 2 Lanes 1-4 in E are HCR-TDN in PBS buffer at room temperature for 0 hours, 2 hours, 6 hours and 10 hours. In summary, Weight-TDN and HCR-TDN can be stably present in PBS buffer at room temperature for 10 hours ( Figure 2 D and E). The above gel images all prove that the tetrahedral structure is successfully assembled and has strong stability within the detection time, which can be used for subsequent exosome recognition and HCR signal amplification experiments.
[0065] Example 2
[0066] Characterization of HER2-associated exosome enrichment capacity
[0067] To explore the ability of tetrahedral structures to extract exosomes, we characterized HEVs extracted from normal breast epithelial cell line MCF-10A, HER2-positive breast tumor cell line SK-BR-3, and HER2-negative breast tumor cell line MD-MBA-231.
[0068] The implementation scheme includes the following methods:
[0069] 1) The conventional centrifugation method was used to extract the exosome solution from SK-BR-3 cells: When the density of the cultured SK-BR-3 cells was 80% to 90%, they were starved for 24 hours with DMEM without 10% fetal bovine serum, and the supernatant of the cell culture was collected by high centrifugation. Then, the supernatant was collected by centrifugation at 300 x g for 10 minutes at 4°C, and then the supernatant was collected by centrifugation at 2000 x g for 10 minutes, and then the supernatant was collected by centrifugation at 10000 x g for 30 minutes to remove the cell debris and collect the supernatant. Finally, the supernatant obtained by centrifugation was filtered with a 0.22 μm filter membrane.
[0070] 2) Traditional ultracentrifugation (Ultra-C): The crude exosome solution of SK-BR-3 cells was centrifuged at 140,000 x g at 4°C for 90 minutes. The supernatant was removed and resuspended in PBS. After another centrifugation at 140,000 x g for 90 minutes at 4°C, the pellet was resuspended in PBS and the above centrifugation step was repeated once. Finally, the supernatant was removed and the exosomes were resuspended in 300 μL PBS.
[0071] 3) Method using TDN-assisted centrifugation (Nano-C): 20 μL of 2 μM Weight-TDN and 20 μL of 2 μM HCR-TDN were added to 160 μL of crude exosome solution from SK-BR-3 cells and incubated at room temperature for 2 hours. Subsequently, free TDN was removed by centrifugation, and 20 μL of 6 μM DX linker was added to the solution obtained after centrifugation and incubated at room temperature for 30 minutes. Centrifuge at 20,000 x g for 30 minutes, remove the supernatant, and collect the target exosome microspheres.
[0072] 4) Dynamic light scattering (DLS) was used to measure the particle size changes of SK-BR-3 cell exosomes obtained by the above two methods: the samples were measured through a 10 mm transparent glass pool. The exosome samples were diluted to an appropriate concentration (approximately 1 mg / mL) in physiological saline and mixed in an ultrasonic water bath for 15 minutes to ensure uniform suspension. At a constant temperature (25°C), the samples were injected into the DLS cell and then subjected to DLS measurements. Each sample was measured 10 times, and each measurement lasted 30 seconds to ensure the reliability of the data. During the measurement, the laser beam passed through the sample and collected the time correlation of the scattered light. The autocorrelation function obtained from the DLS measurement was fitted by the Markov-Monte Carlo method to obtain the size distribution of the particles. The measured data were processed and analyzed by Zetasizer software, including calculation of the average size, aggregation index, and size distribution diagram of the particles.
[0073] 5) Observation of SK-BR-3 cell exosome morphology by transmission electron microscopy (TEM) imaging: Before preparing the sample, the support membrane (copper mesh) was treated with negative glow discharge. Subsequently, 5 μL of the sample solution was drop-cast on the copper mesh, and after 5 minutes, the excess solution on the copper mesh was removed with filter paper. In order to remove the salt in the solution, the copper mesh support membrane was washed with 10 μL of deionized water, and the excess water was removed with filter paper. The sample was negatively stained with 5 μL of 0.7% uranyl acetate solution, and then the excess solution was removed with filter paper. The water on the carbon support membrane was evaporated and dried at room temperature.
[0074] 6) The concentration of SK-BR-3 cell exosomes enriched by these two methods was analyzed using a nanoparticle tracking analysis (NTA) instrument: At a constant temperature (usually 25°C), the sample was injected into the NanoSight sample cup. NTA measurements were performed by setting appropriate parameters (such as laser power, camera exposure time, etc.). The camera captures the Brownian motion of the nanoparticles in the sample and transmits the data to a computer for analysis using the NanoSight software. The software uses the Brownian motion trajectory of a single particle to calculate the size and concentration of the particle. By tracking the nanoparticles in the sample, size distribution graphs and concentration data are generated.
[0075] 7) Blot analysis of exosome surface proteins: The target protein on the surface of exosomes was lysed by a total protein extraction kit and separated by SDS-PAGE. The protein band was transferred to a polyvinylidene fluoride membrane (PVDF) by semi-dry transfer and blocked with 5% (w / v) bovine serum albumin (BSA) in TBST buffer at room temperature for 2 hours. Then, the primary antibodies for CD63 and HER2 were added respectively, and incubated overnight at 4°C with low-speed shaking. The PVDF membrane was then washed 3 times with TBST buffer, and finally incubated with a secondary antibody modified with DyLight800 at room temperature for 1 hour. The PVDF membrane was washed 3 times with TBST buffer, and the protein bands were obtained by the ODYSSEY CLX fluorescence imaging system.
[0076] Exosome characterization was performed as follows:
[0077] First, crude exosomes were isolated from SK-BR-3 cells by centrifugation. Then, they were mixed and incubated with Weight-TDN and HCR-TDN / HER2 at a concentration of 2 μM at room temperature. After centrifugation to remove excess TDN, DX connector was added to induce cross-linking of multiple exosome particles. After another 2-hour incubation, exosomes were enriched by low-speed centrifugation (20,000 × g, 30 min). For comparison, we used conventional ultracentrifugation (Ultra-C) at 1400,00 × g for 90 min twice to enrich crude exosomes. We characterized the concentration of exosomes enriched from the two methods by nanoparticle tracking analysis (NTA). Compared with conventional ultracentrifugation, TDN-assisted centrifugation increased the concentration by 2 times ( Figure 3 A). The particle size changes of exosomes obtained from the two methods were measured by dynamic light scattering (DLS). After adding TDN and DX connectors, the particle size increased significantly from 80nm to 160nm, and small aggregate peaks appeared above 1680nm, indicating the presence of multiple exosome particles that were cross-linked and aggregated ( Figure 3 B). Similar phenomena were observed by transmission electron microscopy (TEM) of exosome particles. Exosomes extracted by conventional ultracentrifugation appeared monodisperse, while exosomes extracted by TDN-assisted centrifugation aggregated into round shapes ( Figure 3C), which indicates that multiple exosomes are in the state of aggregates. In order to verify the membrane surface biomarkers of enriched exosomes, we used western blotting to analyze the expression of CD63 and HER2 on the surface of exosomes derived from normal breast epithelial cell line MCF-10A, HER2-positive breast tumor cell line SK-BR-3 and HER2-negative breast tumor cell line MD-MBA-231 enriched by TDN-assisted centrifugation method (Nano-C). The results showed that CD63 was present in the three groups of samples, the tumor-related marker EpCAM was present in exosomes derived from two breast cancer cell lines, SK-BR-3 and MD-MBA-231, and the abundance of HER2 in exosomes derived from SK-BR-3 was higher than that in exosomes derived from normal breast epithelial and HER2-negative breast tumor cells ( Figure 3 D). All the above results indicate that DNA nanostructures have excellent performance for simple and selective exosome enrichment.
[0078] Example 3
[0079] Plotting a standard curve
[0080] After enrichment of exosomes by Weight-TDN and HCR-TDN / HER2, different concentrations of HEV (NTA assay) were incubated with F-H1-Q and H2, and a linear relationship between the fluorescence signal and the logarithm of the HEV concentration was found, with a high correlation in the range of 2.31×103 to 2.73×107 particles / μL. We recorded the HCR triggering signal of different concentrations of HEV and then determined its working curve ( Figure 3 E).
[0081] Example 4
[0082] Clinical sample testing
[0083] Using the double tetrahedron material, we measured the concentration of clinical samples:
[0084] Screening and diagnosis of HER2-positive breast cancer: Healthy people, patients with benign breast disease and HER2-positive patients ( Figure 4 A);
[0085] Metastasis and prognostic assessment of HER2-positive breast cancer: Patients with non-metastatic and metastatic HER2-positive breast cancer ( Figure 4 B);
[0086] Differentiation of breast cancer patients with different HER2 expression levels: HER2-negative breast cancer patients and HER2-positive breast cancer patients ( Figure 4 C);
[0087] The implementation method is as follows:
[0088] Inclusion and exclusion criteria: patients aged 18 years or older, diagnosed with breast cancer supported by pathology and immunohistochemistry (IHC), patients diagnosed with benign breast lesions by pathology, and healthy individuals from health examination centers. Patients with second primary tumors, other severe or uncontrollable systemic diseases requiring treatment, life expectancy of less than 3 months, pregnancy or breastfeeding were excluded;
[0089] According to the above criteria, 50 healthy subjects, 148 benign patients, and 512 breast cancer patients were included;
[0090] 2-3 ml of peripheral blood was collected using anticoagulation tubes and centrifuged at 3000 rpm for 10 min at 4°C. The supernatant (500 μL) was aspirated, immediately frozen, and stored at -80°C until detection;
[0091] Using double tetrahedral materials for exosome enrichment and detection;
[0092] The exosome levels were compared according to different groups of people.
[0093] The implementation results are as follows:
[0094] Screening and diagnosis of HER2-positive breast cancer: The sera of 50 healthy people, 148 benign patients and 34 HER2-positive breast cancer patients were tested using the tetrahedral structure determination method. The results showed that the HEVs of HER2-positive breast cancer patients were higher than those of healthy people / benign patients.
[0095] Metastasis and prognosis evaluation of HER2-positive breast cancer: The sera of 30 HER2-positive non-metastatic patients and 33 HER2-positive metastatic breast cancer patients were tested using the tetrahedron structure determination method. The results showed that the HEVs of HER2-positive metastatic breast cancer patients were higher than those of non-metastatic HER2-positive breast cancer patients.
[0096] Identification of breast cancer patients with different HER2 expression levels: The sera of 185 HER2-negative patients and 34 HER2-positive breast cancer patients were tested using the tetrahedral structure determination method. The results showed that HEVs in HER2-positive breast cancer patients were higher than those in HER2-negative patients.
[0097] In summary, the detection of HER2-related exosomes using tetrahedral structure has clinical value for the screening diagnosis, metastasis and prognosis evaluation of HER2-positive breast cancer, and it was found that the levels of HER2-related exosomes in breast cancer patients with different HER2 expression levels also differed.
[0098] Although the fluorescence method is used in the above specific embodiments, that is, the FAM group is connected to the HCR trigger sequence to realize detection, it should be understood by those skilled in the art that this method is only for illustrative purposes. After understanding the principle of the present invention, other available detection methods in the industry can also be applied to the present invention, such as nuclide method, antibody method, etc., and such schemes should also be included in the protection scope of the present invention. In addition, for the sequence of assembling nano tetrahedron, although the above specific sequence is used as an example, it should be understood by those skilled in the art that after understanding the principle of the present invention, those skilled in the art can use other sequences to cooperate with CD63 and HER2 aptamers with different sequence structures to make DNA nano tetrahedrons to realize the effect of the present invention, so the above specific sequence should not be limited to the protection scope of the present invention, and the scheme that uses the principle of the present invention to realize the effect of the present invention using other sequence structures should also be included in the protection scope of the present invention. The specific protection scope of the present invention shall be subject to the claims.
[0099] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented and modified over a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without unnecessary experimentation. This application is intended to include any modifications, uses or improvements of the present invention.
[0100] The matters not described in detail in the present invention are all known technologies to those skilled in the art.
[0101] Finally, it should be noted that the above specific implementation methods are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified and replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.
[0102] The description of the sequences used in the specification is shown in Table 1 below.
[0103] Table 1, Description of sequences used in the specification
[0104]
Claims
1. A probe enrichment complex for HER2-related exosome detection, It is characterized in that The complex includes the following two DNA tetrahedron nanomaterials: a precipitated cross-linked tetrahedron and a HER2 recognition tetrahedron, wherein the four vertices of the precipitated cross-linked tetrahedron have overhang chains, one vertex overhang chain contains a CD63 aptamer, and the other three vertex overhang chains can cross-link with each other; the four vertices of the HER2 recognition tetrahedron also have overhang chains, one vertex overhang chain contains a HER2 aptamer, and the other three vertex overhang chains can trigger HCR reactions.
2. The composite according to claim 1, It is characterized in that The precipitation cross-linking tetrahedron is assembled from the nucleotide sequences of SeqNo.1 to 5, the HER2 recognition tetrahedron is assembled from the nucleotide sequences of SeqNo.6 to 10, and further comprises DX connector sequences SeqNo.13 to 14, wherein the DX connector sequences can complement the vertex overhang chains of the precipitation cross-linking tetrahedron for cross-linking and are used for cross-linking of the precipitation cross-linking tetrahedron.
3. The complex according to claim 2, It is characterized in that During assembly, the sequences of SeqNo.1 to 5 were in equal molar ratios, and the sequences of SeqNo.6 to 10 were in equal molar ratios.
4. A kit for detecting HER2-related exosomes, It is characterized in that The kit comprises the following components: the complex according to any one of claims 1 to 3 and an HCR initiating sequence that is complementary to the vertex overhanging chain of the HER2 recognition tetrahedron capable of initiating an HCR reaction, thereby initiating an HCR reaction.
5. The kit according to claim 4, It is characterized in that A detectable group is attached to the HCR initiating sequence.
6. The kit according to claim 5, It is characterized in that The HCR initiation sequence is the sequence shown in SeqNo.11-12.
7. The kit according to claim 4, It is characterized in that The kit also includes a tetrahedron assembly buffer solution, which has the following composition at the use concentration: 40 mM tris(hydroxymethyl)aminomethane, 40 mM glacial acetic acid, 1 mM ethylenediaminetetraacetic acid and 12.5 mM Mg2+, pH=8.
0.
8. The kit according to claim 4, It is characterized in that The kit also includes a control standard, i.e., a HER2-related exosome sample with a known concentration.
9. A method for detecting the concentration of HER2-related exosomes in a sample, It is characterized in that The method comprises the following steps: 1) preparing precipitated cross-linked tetrahedrons and HER2 recognition tetrahedrons, adding them to samples to allow the tetrahedrons to bind to HER2-related exosomes in the samples, wherein the HER2 recognition tetrahedrons contain HCR reaction initiating fragments; 2) Adding double cross-linking structure promotes tetrahedral cross-linking; 3) Enrichment of HER2-associated exosomes; 4) adding an HCR reaction initiator sequence to the enriched HER2-related exosomes, wherein the HCR reaction initiator sequence is connected to a detectable group; 5) Detecting the signal of the detectable group.
10. The method according to claim 9, It is characterized in that The method also includes the steps of drawing a standard curve according to the detection results of the standard substance, and comparing the results obtained by detecting the signal of the detectable group with the standard curve.
